Trisalus Life Sciences, Inc. current report, 12 December 2022

Full document

SEC Form 8-K Summary

Registrant: MedTech Acquisition Corporation, the SPAC pursuing a business combination with TriSalus Life Sciences, Inc. The report concerns stockholder actions on December 12, 2022; the filing was signed and certain notes were issued on December 16, 2022.

Business Context and Reporting Period

MedTech entered into a merger agreement with TriSalus on November 11, 2022. Upon closing, TriSalus is expected to become a wholly owned subsidiary and MedTech is expected to be renamed TriSalus Life Sciences, Inc. The filing reports approval of an extension of the SPAC’s business-combination deadline and related financing arrangements.

Key Financial and Capitalization Matters

  • 23,046,578 public shares were redeemed for approximately $232.37 million, or approximately $10.08 per share.
  • Approximately $19.70 million remained in the trust account after redemptions.
  • Following redemptions, 1,953,422 public shares remained outstanding.
  • The company is required to deposit $0.04 per remaining public share for each month, or portion thereof, during the extension period. The initial deposit was $78,136.88, funded 50% through the Extension Note and 50% by TriSalus.
  • The filing does not provide operating revenue, profit, cash flow, margin, or other conventional business-performance metrics for TriSalus.

Material Changes and Transactions

  • Stockholders approved an amendment extending the deadline to complete an initial business combination from December 22, 2022 to June 22, 2023, or an earlier date set by the board.
  • The Sponsor issued an interest-free Extension Note of up to $468,821.28 to fund deposits into the trust account. It is repayable upon completion of the initial business combination.
  • The Sponsor also issued an unsecured, interest-free Working Capital Note of up to $1.0 million. Amounts may be drawn as needed, and principal is not payable if the company does not complete its business combination within the required period.
  • TriSalus agreed to pay 50% of specified proxy and meeting costs and 50% of trust-account extension deposits. These obligations terminate upon closing or valid termination of the merger agreement, with no repayment obligation to TriSalus for amounts it funded upon termination.
  • All proposals at the special meeting were approved, including the extension amendment and re-election of the listed Class I directors.

Outlook, Risks, and Unusual Items

  • Completion of the TriSalus business combination remains subject to customary conditions, including stockholder approval, satisfaction of minimum-cash requirements after redemptions, and required governmental or regulatory approvals.
  • The transaction may not close by the extended deadline or may be terminated. If no business combination is completed, the trust-account funds are expected to be returned to eligible public stockholders, subject to applicable terms.
  • Key TriSalus risks include reimbursement changes, clinical and regulatory approval uncertainty, commercialization and sales execution, market size, competition, financing needs, partnering, and the ability to manage growth.
  • The substantial redemptions materially reduced the cash available in the trust account and may increase the combined company’s need for additional financing.
  • The referenced Form S-4 registration statement had not yet been declared effective, and the filing does not establish that the business combination will be completed.

Investor Verification Checklist

  • Verify the final trust-account balance, redemption payment amounts, and any subsequent extensions or withdrawals.
  • Review the full Extension Note and Working Capital Note for drawdowns, repayment terms, and any later amendments.
  • Confirm whether the merger agreement was completed, amended, or terminated and whether the proposed name change occurred.
  • Review the eventual Form S-4/proxy statement for transaction consideration, minimum-cash conditions, dilution, financing, and pro forma ownership.
  • Assess TriSalus’s historical and projected revenue, losses, cash burn, debt, regulatory status, reimbursement exposure, and clinical or commercialization milestones.